Subscribe

Hansoh Pharmaceutical Group Company Limited (3692.HK)

HKD32.56 +0.04 (+0.12%)
CN HKSE Healthcare Drug Manufacturers - Specialty & Generic
Address 287 Xiangke Road 201210
Shanghai, JS, CN
CEO Hui Juan Zhong
Website hspharm.com
IPO 2019-06-14
ISIN KYG549581067

Explore sections of this company profile

Description

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD32.56 +0.04 (+0.12%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
11M
Beta
0.52
Float Shares
1.23B
Free Float %
20.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.13% -6.60% -15.26% -10.07% -21.83% -12.86% +21.62% +136.39% -7.12% +61.23% +61.23%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
32.56
DCF (Unlevered) 23.45 -28.0%
DCF (Levered) 28.67 -11.9%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 95% Bullish
Rating 2026-05 Change
Strong Buy 5 0
Buy 16 -2
Hold 1 0
Sell 0 0
Strong Sell 0 -1
Quality scores
Altman Z-Score
24.19
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
7 / 10
Strong MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +22.6% ★ Q4'25: +35.8% (vs Q4'23)
  • ✓
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +27.4% ★ Q4'25: +21.2% (vs Q4'23)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +39.6% ★ Q4'25: +49.7% (vs Q4'23)
  • ✓
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +35.9% ★ Q4'25: +29.6% (vs Q4'23)
  • ✓
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +117.3% ★ Q4'25: +194.7% (vs Q4'23)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +0.5% Q4'25: -1.5% (vs Q4'23)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    0.02× ★ Q4'25: 0.01× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.55) × ERP
WACC = 100% × Ke + 0% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 23.45 Current price: 32.56
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
22 Rev. Ana.
19 EPS Ana. 		Dec 2027
22 Rev. Ana.
17 EPS Ana. 		Dec 2028
19 Rev. Ana.
13 EPS Ana. 		Dec 2029
10 Rev. Ana.
11 EPS Ana. 		Dec 2030
16 Rev. Ana.
5 EPS Ana.
Revenue
8.68B
est: 10.68B (-18.7%)
8.69B
est: 10.63B (-18.2%)
9.94B
est: 11.94B (-16.8%)
9.38B
est: 11.35B (-17.3%)
10.10B
est: 11.25B (-10.2%)
12.26B
est: 12.06B (+1.7%)
15.03B
est: 14.83B (+1.4%)
17.57B
17.15B – 17.95B
+18.5% YoY
19.28B
18.13B – 21.47B
+9.7% YoY
21.97B
21.03B – 23.49B
+14.0% YoY
26.53B
25.40B – 28.38B
+20.8% YoY
30.56B
29.26B – 32.68B
+15.2% YoY
EBITDA
2.98B
est: 3.70B (-19.3%)
2.99B
est: 2.66B (+12.3%)
3.08B
est: 3.24B (-4.7%)
2.93B
est: 4.23B (-30.7%)
4.20B
est: 3.99B (+5.3%)
4.28B
est: 6.91B (-38.1%)
5.77B
est: 5.25B (+9.8%)
6.22B
6.08B – 6.36B
+18.5% YoY
6.83B
6.42B – 7.60B
+9.7% YoY
7.78B
7.45B – 8.32B
+14.0% YoY
9.40B
9.00B – 10.05B
+20.8% YoY
10.82B
10.36B – 11.58B
+15.2% YoY
EBIT
2.78B
est: 3.37B (-17.4%)
2.77B
est: 2.49B (+11.2%)
2.82B
est: 3.03B (-7.0%)
2.61B
est: 3.96B (-34.2%)
3.83B
est: 3.64B (+5.3%)
3.90B
est: 3.89B (+0.2%)
5.40B
est: 4.80B (+12.6%)
5.68B
5.55B – 5.80B
+18.5% YoY
6.24B
5.86B – 6.94B
+9.7% YoY
7.11B
6.80B – 7.60B
+14.0% YoY
8.58B
8.22B – 9.18B
+20.8% YoY
9.88B
9.46B – 10.57B
+15.2% YoY
Net Income
2.56B
est: 2.95B (-13.3%)
2.57B
est: 2.12B (+20.9%)
2.71B
est: 2.58B (+5.0%)
2.58B
est: 2.57B (+0.4%)
3.28B
est: 4.39B (-25.3%)
4.37B
est: 4.36B (+0.2%)
5.56B
est: 4.99B (+11.3%)
6.20B
5.56B – 6.83B
+24.2% YoY
6.90B
5.85B – 7.96B
+11.3% YoY
7.91B
6.64B – 9.17B
+14.6% YoY
11.70B
11.05B – 12.76B
+48.0% YoY
15.27B
14.43B – 16.65B
+30.5% YoY
SGA
4.04B
est: 4.51B (-10.4%)
3.86B
est: 3.36B (+14.9%)
4.37B
est: 4.09B (+7.0%)
4.15B
est: 5.34B (-22.3%)
4.24B
est: 4.47B (-5.1%)
4.51B
est: 4.78B (-5.7%)
4.74B
est: 5.88B (-19.5%)
6.98B
6.81B – 7.12B
+18.5% YoY
7.65B
7.20B – 8.52B
+9.7% YoY
8.72B
8.35B – 9.33B
+14.0% YoY
10.53B
10.08B – 11.26B
+20.8% YoY
12.13B
11.61B – 12.97B
+15.2% YoY
EPS
0.47
est: 0.50 (-5.2%)
0.44
est: 0.54 (-18.1%)
0.46
est: 0.56 (-17.8%)
0.44
est: 0.52 (-15.7%)
0.50
est: 0.74 (-32.4%)
0.74
est: 0.70 (+6.3%)
0.93
est: 0.88 (+5.9%)
1.02
0.93 – 1.14
+16.1% YoY
1.13
0.98 – 1.33
+10.4% YoY
1.28
1.11 – 1.53
+13.9% YoY
1.96
1.85 – 2.13
+52.6% YoY
2.55
2.41 – 2.78
+30.5% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B+ 3/5 4/5 4/5 5/5 4/5 1/5 1/5
2026-05-28 B+ 3/5 4/5 4/5 5/5 4/5 1/5 1/5
2026-05-27 B+ 3/5 4/5 4/5 5/5 4/5 1/5 1/5
2026-05-26 B+ 3/5 4/5 4/5 5/5 4/5 1/5 1/5
2026-05-22 B+ 3/5 4/5 4/5 5/5 4/5 1/5 1/5
2026-05-21 B+ 3/5 4/5 4/5 5/5 4/5 1/5 1/5
2026-05-20 B+ 3/5 4/5 4/5 5/5 4/5 1/5 1/5
2026-05-19 B+ 3/5 4/5 4/5 5/5 4/5 1/5 1/5
2026-05-18 B+ 3/5 4/5 4/5 5/5 4/5 1/5 1/5
2026-05-15 A- 4/5 4/5 5/5 5/5 4/5 1/5 1/5
2026-05-14 A- 4/5 4/5 5/5 5/5 4/5 1/5 1/5
2026-05-13 A- 4/5 4/5 4/5 5/5 4/5 2/5 1/5
2026-05-12 A- 4/5 4/5 4/5 5/5 4/5 2/5 1/5
2026-05-11 A- 4/5 4/5 4/5 5/5 4/5 2/5 1/5
2026-05-08 A- 4/5 3/5 4/5 5/5 4/5 2/5 2/5
2026-05-07 A- 4/5 3/5 4/5 5/5 4/5 2/5 2/5
2026-05-06 A- 4/5 3/5 4/5 5/5 4/5 2/5 2/5
2026-05-05 B+ 3/5 3/5 4/5 5/5 3/5 2/5 1/5
2026-05-04 B+ 3/5 3/5 4/5 5/5 3/5 2/5 1/5
2026-04-30 B+ 3/5 3/5 4/5 5/5 3/5 2/5 1/5
2026-04-29 B+ 3/5 3/5 4/5 5/5 3/5 2/5 1/5
2026-04-28 B+ 3/5 3/5 4/5 5/5 3/5 2/5 1/5
2026-04-27 B+ 3/5 3/5 4/5 5/5 3/5 2/5 2/5
2026-04-24 B+ 3/5 3/5 4/5 5/5 3/5 2/5 2/5
2026-04-23 B+ 3/5 3/5 4/5 5/5 2/5 2/5 2/5
2026-04-22 B+ 3/5 3/5 4/5 5/5 2/5 2/5 2/5
2026-04-21 B+ 3/5 3/5 4/5 5/5 2/5 2/5 2/5
2026-04-20 B+ 3/5 3/5 4/5 5/5 2/5 2/5 2/5
2026-04-17 B+ 3/5 3/5 4/5 5/5 2/5 2/5 2/5
2026-04-16 B+ 3/5 3/5 4/5 5/5 2/5 2/5 2/5
2026-04-15 B+ 3/5 3/5 4/5 5/5 2/5 2/5 2/5
2026-04-14 B+ 3/5 3/5 4/5 5/5 2/5 2/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
7.26B
OE per share TTM
1.21
Owner's Yield
3.85%
Maintenance CapEx ratio
27.92%
Maint CapEx / Avg PPE
29.9%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
577.9K
Shares Outstanding
6.06B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Huijuan Zhong Founder, Chairlady & Chief Executive Officer 14M female
Aifeng Lyu Executive Director 4M male
Yuan Sun Executive Director 4M female
Chih-Hung Lee Chief Science Officer — —
Leong Yin Lee Joint Company Secretary — male
Min Hu Chief Financial Officer — male
Shan Jiang Chief Technology Officer — —
Shengli Zhong Joint Company Secretary & Senior Vice President — female
Weiyong Sun Chief Business Officer — male
Xiaoqing Zhang Chief Medical Officer — —
Chuanhe Xu Senior Vice President — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic